ACM  >> Vol. 5 No. 2 (June 2015)

    基因修饰的骨髓间充质干细胞移植治疗帕金森病的研究进展
    Research Progress of Genetic Modified Bone Marrow Mesenchymal Stem Cell Transplantation for the Therapy of Parkinson’s Disease

  • 全文下载: PDF(369KB) HTML   XML   PP.95-102   DOI: 10.12677/ACM.2015.52017  
  • 下载量: 777  浏览量: 5,748   国家自然科学基金支持

作者:  

薛 莹,潘士锋,邢 华:扬州大学兽医学院,江苏 扬州

关键词:
帕金森病骨髓间充质干细胞基因治疗Parkinson’s Disease Bone Mesenchymal Stem Cells Gene Therapy

摘要:

帕金森病进展缓慢,以神经退化为特征,主要病因是选择性中脑黑质多巴胺能神经元的丧失和纹状体多巴胺含量的显著减少。传统疗法有药物治疗和外科治疗,而近来较理想是基因治疗和干细胞移植治疗,包括胚胎干细胞、神经干细胞和间充质干细胞等。骨髓间充质干细胞作为体内一种多功能干细胞,具有成为基因治疗靶细胞的显著优势,并已被普遍用于人类疾病的研究。然而,对帕金森病进行基因治疗的目的基因选择具有多样性。因此,本文主要针对近十年基因治疗帕金森病的目的基因的选择相关研究进展作一综述。

Parkinson’s disease (PD) is a neurodegenerative disease characterized by progressive degeneration of nigrostriatal dopaminergic (Dopamine, DA) neurons and reduced concentration of striatal dopamine. Traditional therapies for Parkinson’s disease are medication and surgery, while gene therapy and stem-cell therapy have been considered as much more ideal methods recently, such as embryonic stem cells, neural stem cells and mesenchymal stem cells, etc. Bone mesenchymal stem cells as a kind of pluripotent stem cells in the body are widely used in the related human diseases for the superiority to be the target cells of gene therapy. However, choosing appropriate target genes for therapy of Parkinson’s disease has a great diversity, therefore, here I summarize the researches of the theraphy methods of Parkinson’s disease in recent 10 years.

文章引用:
薛莹, 潘士锋, 邢华. 基因修饰的骨髓间充质干细胞移植治疗帕金森病的研究进展[J]. 临床医学进展, 2015, 5(2): 95-102. http://dx.doi.org/10.12677/ACM.2015.52017

参考文献

[1] 李颖 (2011) 健康管理与慢病防控系列报告之二十. 科技日报.
[2] Yuan, H., Zhang, Z.W., Liang, L.W., et al. (2010) Treatment strategies for Parkinson’s disease. Neuroscience Bulletin, 26, 66-76.
[3] Beal, M.F. (2001) Expe-rimental model of Parkinson’s disease. Nature Reviews Neuroscience, 2, 325-334.
[4] Bronte Stewart, H. (2003) Par-kinson’s disease: Surgical options. Current Treatment Options in Neurology, 5, 131-147.
[5] 苏平 (2005) BDNF基因修饰的人骨髓间充质干细胞移植治疗帕金森病的实验研究. 广州同和第一军医大学, 广州.
[6] 季正剑 (2011) 骨髓间充质干细胞移植治疗帕金森病的实验研究. 扬州大学, 扬州.
[7] 张俊 (2010) 应用神经营养因子治疗帕金森病的研究现状. 中国微侵袭神经外科杂志, 15, 570-573.
[8] Gash, D.M., Gerhardt, G.A., et al. (1998) Effects of glial cell line-derived neurotrophic factoron the nigrostriatal dopamine system in rodents and nonhuman primate. Advances in Pharmacology, 42, 911-915.
[9] 孙兵, 惠国桢, 郭礼和 (2004) 表达GDNF的骨髓间充质干细胞治疗帕金森病的实验研究. 苏州大学, 苏州.
[10] 苏雅茹 (2006) GDNF在BMSCs中的表达及其对乳胞素所致帕金森病模型的保护作用. 复旦大学华山医院, 上海.
[11] Shi, D., Chen, G., Lv, L., Li, L., Wei, D., Gu, P., et al. (2011) The effect of lentivirus-mediated TH and GDNF genetic engineering mesenchymal stem cells on Parkinson’s disease rat model. Neurological Sciences, 32, 41-45.
[12] Glavaski-Joksimovic, A., Virag, T., Mangatu, T.A., McGrogan, M., Wang, X.S. and Bohn, M.C. (2010) Glial cell line- derived neurotrophic factor-secreting genetically modified human bone marrow-derived mesenchymal stem cells promote recovery in a rat model of Parkinson’s disease. Journal of Neuroscience Research, 88, 2669-2681.
[13] Moloney, T.C., Rooney, G.E., Barry, F.P., Howard, L. and Dowd, E. (2010) Potential of rat bone marrow-derived mesenchymal stem cells as vehicles for delivery of neurotrophins to the Parkinsonian rat brain. Brain Research, 1359, 33- 43.
[14] Yang, W.H., Yang, C., Xue, Y.Q., Lu, T., Reiser, J., Zhao, L.R. and Duan, W.M. (2013) Regulated expression of lentivirus-mediated GDNF in human bone marrow-derived mesenchymal stem cells and its neuroprotection on dopaminergic cells in vitro. PLoS ONE, 8, e64389.
[15] Wang, T.H., Feng, Z.-T., Wei, P., Li, H., Shi, Z.-J. and Li, L.-Y. (2008) Effects of pcDNA3-β-NGF gene-modified BMSC on the rat model of Parkinson’s disease. Journal of Molecular Neuroscience, 35, 161-169.
[16] 朱晓东 (2010) NGF、Noggin基因修饰的rBMSCs移植治疗帕金森病大鼠模型的实验研究. 博士论文, 天津医科大学, 天津.
[17] 毕涌, 洪娟, 林晓滨, 李晓莉, 魏鹏, 施镇江等 (2014) 人β-NGF基因修饰的骨髓间充质干细胞对帕金森病大鼠行为学的影响. 中国病理生理杂志, 3, 473-478.
[18] 黄月 (2011) TH-NTN基因修饰的骨髓间充质干细胞治疗帕金森病模型大鼠的实验研究. 博士论文, 郑州大学第一临床学院, 郑州.
[19] 张平, 赵钢勇, 宋月平, 苏立凯 (2012) 转染pIRESneo-EGFP-BDNF的骨髓间充质干细胞侧脑室注射对帕金森大鼠行为学的影响. 山东医药, 26, 23-26.
[20] Huang, Y., Chang, C., Zhang, J.W. and Gao, X.Q. (2012) Bone marrow-derived mesenchymal stem cells increase dopamine synthesis in the injured striatum. Neural Regeneration Research, 7, 2653-2662.
[21] 韩暄 (2012) CDNF对多巴胺能神经元神经保护作用的实验研究. 博士论文, 安徽医科大学, 合肥.
[22] Yin, X.F., Xu, H.M., Jiang, Y.X., Deng, W.S., Wu, Z.Y., Xiang, H.W., et al. (2014) The effect of lentivirus-mediated PSPN genetic engineering bone marrow mesenchymal stem cells on Parkinson’s disease rat model. PLoS ONE, 9, e105118.
[23] Zetterström, R.H., Williams, R., Perlmann, T. and Olson, L. (1996) Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Molecular Brain Research, 41, 111-120.
[24] 徐浩文, 朱蔚文, 叶钦勇, 刘焯霖, 徐评议, 黎锦如 (2005) 经Nuur1基因转染的骨髓间充质干细胞移植对帕金森病大鼠旋转行为及纹状体多种神经因子的影响. 中国临床康复, 22, 56-60.
[25] Nagatsu, T. (1991) Genes for human catecholamine-synthesizing enzymes. Neuroscience Research, 12, 315-345.
[26] Lu, L., Zhao, C., Liu, Y., Sun, X., Duan, C., Ji, M., et al. (2005) Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson’s disease. Brain Research Protocols, 15, 46-51.
[27] 鲁玲玲, 赵焕英, 吴均, 杨慧 (2009) 多巴胺合成相关酶基因联合治疗帕金森病大鼠模型的研究. 中国生物工程杂志, 2, 34-41.
[28] 刘晓艳, 康慧聪, 胡琦, 许峰, 朱遂强 (2010) 酪氨酸羟化酶和核受体相关因子1基因共转染大鼠骨髓间充质干细胞的实验研究. 中国临床神经科学, 1, 1-4.
[29] 张易 (2012) 大鼠纹状体内注射LV-Shh促进帕金森模型大鼠神经再生. 硕士论文, 南方医科大学, 广州.